Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

M. Talpaz, R. Hehlmann, A. Quintás-Cardama, J. Mercer, J. Cortes

Research output: Contribution to journalReview article

Abstract

Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, imatinib cannot eradicate CML primitive progenitors, which likely accounts for the high relapse rate when imatinib is discontinued. IFNα, unlike imatinib, preferentially targets CML stem cells. Early studies with IFNα in CML demonstrated its ability to induce cytogenetic remission. Moreover, a small percentage of patients treated with IFNα were able to sustain durable remissions after discontinuing therapy and were probably cured. The mechanisms by which IFNα exerts its antitumor activity in CML are not well understood; however, activation of leukemia-specific immunity may have a role. Some clinical studies have demonstrated that the combination of imatinib and IFNα is superior to either therapy alone, perhaps because of their different mechanisms of action. Nonetheless, the side effects of IFNα often impede its administration, especially in combination therapy. Here, we review the role of IFNα in CML treatment and the recent developments that have renewed interest in this once standard therapy for patients with CML.

Original languageEnglish (US)
Pages (from-to)803-812
Number of pages10
JournalLeukemia
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Therapeutics
Myeloid Progenitor Cells
Busulfan
Hydroxyurea
Cytogenetics
Protein-Tyrosine Kinases
Imatinib Mesylate
Immunity
Leukemia
Recurrence
Drug Therapy

Keywords

  • chronic myeloid leukemia
  • imatinib
  • interferon-a
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. / Talpaz, M.; Hehlmann, R.; Quintás-Cardama, A.; Mercer, J.; Cortes, J.

In: Leukemia, Vol. 27, No. 4, 01.04.2013, p. 803-812.

Research output: Contribution to journalReview article

Talpaz, M, Hehlmann, R, Quintás-Cardama, A, Mercer, J & Cortes, J 2013, 'Re-emergence of interferon-α in the treatment of chronic myeloid leukemia', Leukemia, vol. 27, no. 4, pp. 803-812. https://doi.org/10.1038/leu.2012.313
Talpaz, M. ; Hehlmann, R. ; Quintás-Cardama, A. ; Mercer, J. ; Cortes, J. / Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. In: Leukemia. 2013 ; Vol. 27, No. 4. pp. 803-812.
@article{d372b2ea374f4cc59c6460c412686536,
title = "Re-emergence of interferon-α in the treatment of chronic myeloid leukemia",
abstract = "Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, imatinib cannot eradicate CML primitive progenitors, which likely accounts for the high relapse rate when imatinib is discontinued. IFNα, unlike imatinib, preferentially targets CML stem cells. Early studies with IFNα in CML demonstrated its ability to induce cytogenetic remission. Moreover, a small percentage of patients treated with IFNα were able to sustain durable remissions after discontinuing therapy and were probably cured. The mechanisms by which IFNα exerts its antitumor activity in CML are not well understood; however, activation of leukemia-specific immunity may have a role. Some clinical studies have demonstrated that the combination of imatinib and IFNα is superior to either therapy alone, perhaps because of their different mechanisms of action. Nonetheless, the side effects of IFNα often impede its administration, especially in combination therapy. Here, we review the role of IFNα in CML treatment and the recent developments that have renewed interest in this once standard therapy for patients with CML.",
keywords = "chronic myeloid leukemia, imatinib, interferon-a, tyrosine kinase inhibitor",
author = "M. Talpaz and R. Hehlmann and A. Quint{\'a}s-Cardama and J. Mercer and J. Cortes",
year = "2013",
month = "4",
day = "1",
doi = "10.1038/leu.2012.313",
language = "English (US)",
volume = "27",
pages = "803--812",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

AU - Talpaz, M.

AU - Hehlmann, R.

AU - Quintás-Cardama, A.

AU - Mercer, J.

AU - Cortes, J.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, imatinib cannot eradicate CML primitive progenitors, which likely accounts for the high relapse rate when imatinib is discontinued. IFNα, unlike imatinib, preferentially targets CML stem cells. Early studies with IFNα in CML demonstrated its ability to induce cytogenetic remission. Moreover, a small percentage of patients treated with IFNα were able to sustain durable remissions after discontinuing therapy and were probably cured. The mechanisms by which IFNα exerts its antitumor activity in CML are not well understood; however, activation of leukemia-specific immunity may have a role. Some clinical studies have demonstrated that the combination of imatinib and IFNα is superior to either therapy alone, perhaps because of their different mechanisms of action. Nonetheless, the side effects of IFNα often impede its administration, especially in combination therapy. Here, we review the role of IFNα in CML treatment and the recent developments that have renewed interest in this once standard therapy for patients with CML.

AB - Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, imatinib cannot eradicate CML primitive progenitors, which likely accounts for the high relapse rate when imatinib is discontinued. IFNα, unlike imatinib, preferentially targets CML stem cells. Early studies with IFNα in CML demonstrated its ability to induce cytogenetic remission. Moreover, a small percentage of patients treated with IFNα were able to sustain durable remissions after discontinuing therapy and were probably cured. The mechanisms by which IFNα exerts its antitumor activity in CML are not well understood; however, activation of leukemia-specific immunity may have a role. Some clinical studies have demonstrated that the combination of imatinib and IFNα is superior to either therapy alone, perhaps because of their different mechanisms of action. Nonetheless, the side effects of IFNα often impede its administration, especially in combination therapy. Here, we review the role of IFNα in CML treatment and the recent developments that have renewed interest in this once standard therapy for patients with CML.

KW - chronic myeloid leukemia

KW - imatinib

KW - interferon-a

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84876100195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876100195&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.313

DO - 10.1038/leu.2012.313

M3 - Review article

C2 - 23238589

AN - SCOPUS:84876100195

VL - 27

SP - 803

EP - 812

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -